Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
National University Corporation Tottori University manages 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are distributed across several distinct examiners and 4 distinct art units. Eric Brandon Wright is the busiest examiner for the university, handling 1 pending office action. The distribution of actions across 4 distinct art units suggests a diverse range of biological and pharmaceutical research being patented by the institution.
Because each pending action is assigned to a different examiner, the university's prosecution is decentralized across the patent office's biotechnology divisions. For practitioners, this variety means that prosecution strategies must be tailored to the specific standards of multiple examination groups. The use of 4 distinct examiners indicates that the university's research covers several different technical classifications, requiring a broad approach to managing its current intellectual property portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WRIGHT, ERIC BRANDON | 1 | — | — |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251805 | METHOD FOR PRODUCING REVERSIBLY IMMORTALIZED CELL | VIJAYARAGHAVAN, JAGAMYA NMN | 23d overdue |
| 18023957 | ANTIBODY AGAINST CORONAVIRUS | TAYLOR, LIA ELAN | 19d |
| 18693293 | METHOD FOR PRODUCING HUMAN ARTIFICIAL CHROMOSOME VECTOR IN HUMAN CELL | WRIGHT, ERIC BRANDON | — |
| 18246592 | ONCOLYTIC VACCINIA VIRUS DEFICIENT IN LARGE REGION OF GENES | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251805 | METHOD FOR PRODUCING REVERSIBLY IMMORTALIZED CELL | VIJAYARAGHAVAN, JAGAMYA NMN | 23d overdue |
| 18023957 | ANTIBODY AGAINST CORONAVIRUS | TAYLOR, LIA ELAN | 19d |
| 18246592 | ONCOLYTIC VACCINIA VIRUS DEFICIENT IN LARGE REGION OF GENES | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1633 | 1 |
| 1631 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18693293 | METHOD FOR PRODUCING HUMAN ARTIFICIAL CHROMOSOME VECTOR IN HUMAN CELL | WRIGHT, ERIC BRANDON | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18251805 | METHOD FOR PRODUCING REVERSIBLY IMMORTALIZED CELL | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Non-Final OA | 23d overdue | Pending | May 04, 2023 |
| 18246592 | ONCOLYTIC VACCINIA VIRUS DEFICIENT IN LARGE REGION OF GENES | BATES, KEENAN ALEXANDER | 1631 | §102§112 | Non-Final OA | — | Pending | Mar 24, 2023 |
| 18023957 | ANTIBODY AGAINST CORONAVIRUS | TAYLOR, LIA ELAN | 1641 | §102§103§112 | Final Rejection | 19d | Pending | Feb 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial